Drug Trial Radar · NCT05298449
Phase 2 of HU-045 in Glabellar Lines
Last checked: Nov 19, 2026Latest source record: Jul 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Mar 28, 2022
Primary completion
Nov 7, 2022
Study completion Apr 25, 2023
Sponsor
- Lead sponsor
- Huons Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
Conditions
- Glabellar Lines
Interventions
HU-045Drug
HU-045 is a medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use. White powder
Xeomin®Drug
Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants whose glabellar lines at maximal frown are improvedTime frame: Week4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chung-Ang University
Seoul, Dongjak-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.